EBR/GZR (elbasvir/grazoprevir) — Competitive Intelligence Brief

EBR/GZR (elbasvir/grazoprevir) (EBR/GZR (elbasvir/grazoprevir)) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct-acting antiviral (DAA) combination; NS5A inhibitor + NS3/4A protease inhibitor. Area: Infectious Disease / Virology.

marketed Direct-acting antiviral (DAA) combination; NS5A inhibitor + NS3/4A protease inhibitor Hepatitis C virus NS5A protein and NS3/4A serine protease Infectious Disease / Virology Small molecule

Target snapshot

EBR/GZR (elbasvir/grazoprevir) (EBR/GZR (elbasvir/grazoprevir)) — University of Florida. Elbasvir/grazoprevir is a fixed-dose combination of an NS5A inhibitor and an NS3/4A protease inhibitor that blocks hepatitis C virus replication.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
EBR/GZR (elbasvir/grazoprevir) TARGET	EBR/GZR (elbasvir/grazoprevir)	University of Florida	marketed	Direct-acting antiviral (DAA) combination; NS5A inhibitor + NS3/4A protease inhibitor	Hepatitis C virus NS5A protein and NS3/4A serine protease
EBR/GZR	EBR/GZR	Dallas VA Medical Center	marketed	Direct-acting antiviral combination (NS5A inhibitor + NS3/4A protease inhibitor)	Hepatitis C virus NS5A protein and NS3/4A serine protease
Daclatasvir plus Asunaprevir	Daclatasvir plus Asunaprevir	Myeong Jun Song	marketed	Direct-acting antiviral combination (NS5A inhibitor + NS3/4A protease inhibitor)	HCV NS5A protein and HCV NS3/4A serine protease
Sofosbuvir/Velpatasvir/Voxilaprevir	Sofosbuvir/Velpatasvir/Voxilaprevir	Peking University People's Hospital	marketed	Direct-acting antiviral (DAA) combination; NS5B polymerase inhibitor + NS5A inhibitor + NS3/4A protease inhibitor	HCV NS5B polymerase, HCV NS5A protein, HCV NS3/4A protease
Elbasvir/Grazoprevir	Elbasvir/Grazoprevir	University of Florence	marketed	Direct-acting antiviral (DAA) combination; NS5A inhibitor + NS3/4A protease inhibitor	HCV NS5A protein and HCV NS3/4A serine protease
Elbasvir/Grazoprevir Fixed Dose Combination	Elbasvir/Grazoprevir Fixed Dose Combination	University Hospital, Clermont-Ferrand	phase 3	HCV direct-acting antiviral combination (NS5A inhibitor + NS3/4A protease inhibitor)	HCV NS5A protein and HCV NS3/4A serine protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct-acting antiviral (DAA) combination; NS5A inhibitor + NS3/4A protease inhibitor class)

1. University of Florence · 1 drug in this class
2. University of Florida · 1 drug in this class